(-0.10%) 5 463.83 points
(-0.09%) 39 076 points
(0.15%) 17 745 points
(-0.72%) $80.25
(-4.32%) $2.64
(-0.83%) $2 311.40
(0.01%) $28.87
(2.32%) $1 009.30
(0.29%) $0.936
(0.73%) $10.68
(0.49%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States...
Stats | |
---|---|
Today's Volume | 62 096 |
Average Volume | 609 125 |
Market Cap | 47.34M |
EPS | $-0.300 ( Q1 | 2024-05-09 ) |
Next earnings date | ( $-0.320 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.470 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00200 (0.31%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-20 | Wallace Courtney | Buy | 50 000 | Stock Option (right to buy) |
2024-06-20 | Garner Elizabeth | Buy | 50 000 | Stock Option (right to buy) |
2024-06-20 | Cooper Graham K | Buy | 50 000 | Stock Option (right to buy) |
2024-06-20 | Klearman Micki | Buy | 50 000 | Stock Option (right to buy) |
2024-06-20 | Kauffman Michael | Buy | 50 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
-10.04 |
Last 100 transactions |
Buy: 7 765 931 | Sell: 10 044 723 |
Volume Correlation
Kezar Life Sciences Inc Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations | |
---|---|
RILYM | -0.809 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Kezar Life Sciences Inc Correlation - Currency/Commodity
Kezar Life Sciences Inc Financials
Annual | 2023 |
Revenue: | $7.00M |
Gross Profit: | $5.93M (84.77 %) |
EPS: | $-1.400 |
FY | 2023 |
Revenue: | $7.00M |
Gross Profit: | $5.93M (84.77 %) |
EPS: | $-1.400 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $-1.02M (0.00 %) |
EPS: | $-0.970 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-0.00102 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Kezar Life Sciences Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators